Biogen, Alkermes Settle Patent Suit with Teva on Vumerity Copies

Biogen and Alkermes had claimed that Teva’s proposed generic version of Vumerity infringes three patents for the multiple sclerosis drug that Alkermes licenses exclusively to Biogen.

• No details provided in stipulation and proposed order of dismissal, approved Friday in federal court in Wilmington, Delaware
• Patents cover drug’s active ingredient, diroximel fumarate, and its use in treating MS, and expire in September 2033: FDA Orange Book
• Biogen has predicted $1 billion peak-sales potential for Vumerity, though Bloomberg Intelligence analyst Marc Engelsgjerd said July 22that reaching that figure “seems a tall order”
• EARLIER: Biogen Target Slashed At Guggenheim as Aduhelm ...